The Impella CP heart pump is being used more and more to treat cardiogenic shock, and the benefits are clear. For many older patients, however, the technology seem to fall short.
The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
In an exclusive video, Stacey Wolfson, MD, and Beatriu Reig, MD, MPH, from the NYU Grossman School of Medicine, discuss the findings of their new analysis.